There is ongoing work in the field of "off the shelf" engineered cell therapy. Current strategies include: - banks of products with major HLA types, so that so

There is ongoing work in the field of "off the shelf" engineered cell therapy. Current strategies include: - banks of products with major HLA types, so that some matching is still required, but you don't need a 1:1 donor as with bone marrow transplant - stripping, downregulation, or ablation of proteins that coudl cause rejection (eg HLA class II) - expression of other tolerance signals Here is a brief editorial on a paper using some of these stratgies: https://www.nature.com/articles/s41422-022-00745-4 https://www.nature.com/articles/s41422-022-00745-4 Here is a more comprehensive review article: https://ehoonline.biomedcentral.com/articles/10.1186/s40164-023-00435-w https://ehoonline.biomedcentral.com/articles/10.1186/s40164-...